Hemoglobin News and Research RSS Feed - Hemoglobin News and Research

NIH-funded Growing Resilience project to evaluate health impacts of food gardens

NIH-funded Growing Resilience project to evaluate health impacts of food gardens

With a five-year, $2.5 million grant from the National Institutes of Health, University of Wyoming and Wind River Indian Reservation partners will evaluate the health impacts of food gardens with 100 Eastern Shoshone and Northern Arapaho families who would like to try home gardening. [More]
New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

New study compares effectiveness of tinzaparin and warfarin in patients with active cancer, recurrent VTE

Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA. [More]
Researchers find CD163 protein limits muscle repair after ischemic injury

Researchers find CD163 protein limits muscle repair after ischemic injury

Researchers have identified a protein produced by white blood cells that puts the brakes on muscle repair after injury. By removing the protein CD163 from mice, scientists at Emory University School of Medicine could boost muscle repair and recovery of blood flow after ischemic injury (damage caused by restriction of blood flow). [More]
Research suggests that only one in three older Americans have diabetes under control

Research suggests that only one in three older Americans have diabetes under control

Only one in three older Americans have their diabetes under control as measured by guidelines set by the American Diabetes Association, new Johns Hopkins Bloomberg School of Public Health research suggests. [More]
Tips to prevent, treat black widow and brown recluse spider bites

Tips to prevent, treat black widow and brown recluse spider bites

Most spiders are non-venomous and most spider bites are harmless. They may cause some local redness and pain, but can usually be managed at home by washing, applying ice and keeping the area clean. [More]
IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. [More]
Researchers pinpoint two biomarkers elevated in severe form of coronary disease

Researchers pinpoint two biomarkers elevated in severe form of coronary disease

Insulin resistance affects tens of millions of Americans and is a big risk factor for heart disease. Yet, some people with the condition never develop heart disease, while some experience moderate coronary blockages. Others, though, get severe atherosclerosis - multiple blockages and deterioration of coronary arteries characterized by thick, hard, plaque-ridden arterial walls. [More]
Discovery reveals possibility of using water for finer analysis of the brain's functioning

Discovery reveals possibility of using water for finer analysis of the brain's functioning

To observe the brain in action, scientists and physicians use imaging techniques, among which functional magnetic resonance imaging (fMRI) is the best known. These techniques are not based on direct observations of electric impulses from activated neurons, but on one of their consequences. Indeed, this stimulation triggers physiological modifications in the activated cerebral region, changes that become visible by imaging. [More]
Study: Umbilical cord milking improves blood pressure, red blood cell levels in preterm infants

Study: Umbilical cord milking improves blood pressure, red blood cell levels in preterm infants

A technique to increase the flow of blood from the umbilical cord into the infant's circulatory system improves blood pressure and red blood cell levels in preterm infants delivered by Cesarean section, according to a study funded by the National Institutes of Health. [More]
New report on global market for point of care diagnostics

New report on global market for point of care diagnostics

The market for point of care diagnostics reached $17 billion, in 2014, according to Kalorama Information. The term refers to diagnostic tests performed outside the central laboratory or decentralized. [More]
Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics announces FDA approval of VITROS Chemistry Products HbA1c Reagent Kit for diagnosis of diabetes

Ortho Clinical Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the VITROS Chemistry Products HbA1c Reagent Kit to be used on the VITROS 5600 Integrated System, VITROS 4600 Chemistry System, and the VITROS 5,1 FS Chemistry System. The test can be used for the quantitative determination of percent glycated hemoglobin A1c (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in human whole blood. [More]
New UT Southwestern research shows that exercise can improve diabetes control

New UT Southwestern research shows that exercise can improve diabetes control

Diabetics who exercise can trim waist size and body fat, and control blood glucose, even if they don't see cardiorespiratory benefits, new research by UT Southwestern Medical Center cardiologists shows. [More]
FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan. [More]
Point of care measurement of hemoglobin: an interview with Katja Lemburg, EKF Diagnostics

Point of care measurement of hemoglobin: an interview with Katja Lemburg, EKF Diagnostics

Katja Lemburg discusses the next generation Hemo Control being launched in Europe at EuroMedLab, Paris 21-25th June. EKF will be exhibiting on Stand G005 (Level 1). [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Keeping blood sugar levels under control can help protect hearts from diabetes-related damage

Day in and day out, for years on end, millions of people with diabetes prick their fingers to test their blood sugar level. And many may wonder if all the careful eating, exercise and medication it takes to keep those levels under control is really worth it. [More]
Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone. [More]
Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors. [More]
Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. [More]
Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR. [More]
Advertisement